Breast cancer biology, hormone receptors, subtype frequency, and mutations can evolve over time under the pressure of systemic therapy; therefore, pretreatment tumor specimens may have different biomarker expressions than post-treatment tumor specimens. This evidence concerns the gene NR4A1 and breast cancer.